Tositumomab
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Overview
Tositumomab was a drug that was approved for the treatment of relapsed or chemotherapy/rituxan–refractory Non-Hodgkin lymphoma in 2003.[1] It was sold in the U.S. and Canada under the trade name Bexxar. Sale of the drug was discontinued and marketing approval was withdrawn in February 2014 due to the decline in usage (fewer than 75 patients in 2012) and the existence of other similar drugs.[2][3]
This drug combination was developed by Corixa which was purchased by GlaxoSmithKline) in 2005.[4]
References
References
- ↑ New York Times. July 1, 2003 Company News: Corixa and Glaxo’s Cancer Drug Wins FDA Approval
- ↑ “Why Good Drugs Sometimes Fail: The Bexxar Story”.
- ↑ Notice by the Food and Drug Administration on October 23, 2013. GlaxoSmithKline LLC; Withdrawal of Approval of the Indication for Treatment of Patients With Relapsed or Refractory, Low Grade, Follicular, or Transformed CD20 Positive Non-Hodgkin’s Lymphoma Who Have Not Received Prior Rituximab; BEXXAR
- ↑ Carla Mozee for MarketWatch. April 29, 2005 Glaxo to acquire Corixa for $300 million
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH